Wang et al. designed OVs to include the chemotactic cytokine, or “chemokine”, CXCL11, and found that coadministration of OVs increases the therapeutic efficacy of B7-H3-CAR T-cells against GBM tumors [67] (Table 2). The gene discussed is CXCL11; the disease is glioblastoma.